Skip to main
ANEB
ANEB logo

Anebulo Pharmaceuticals (ANEB) Stock Forecast & Price Target

Anebulo Pharmaceuticals (ANEB) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anebulo Pharmaceuticals Inc is poised for potential upward momentum due to anticipated positive milestones surrounding its lead product candidate, ANEB-001, which addresses the increasing concern of cannabinoid overdose amid rising THC potency and legalization efforts. The company’s market opportunity is further bolstered by a $1.9 million cooperative grant from NIDA to develop an intravenous formulation of ANEB-001, highlighting regulatory support for its innovative approach. Clinical studies demonstrate that ANEB-001 is rapidly absorbed, well tolerated, and effectively contributes to weight loss, reinforcing its viability in treating acute cannabis overdose and enhancing the company’s growth potential.

Bears say

Anebulo Pharmaceuticals has experienced a significant decline in share value since its Initial Public Offering in May 2021, reflecting broader market trends. The company is projected to incur a net loss of $5.6 million for fiscal 2025, which represents a continuing trend of financial losses, including a reported net loss of $8.2 million for the fiscal year ending June 2024. Additionally, the decrease in losses from $11.7 million in fiscal 2023 to $8.2 million in fiscal 2024 indicates only a marginal improvement, which may raise concerns about the company’s financial sustainability and growth prospects.

Anebulo Pharmaceuticals (ANEB) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anebulo Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anebulo Pharmaceuticals (ANEB) Forecast

Analysts have given Anebulo Pharmaceuticals (ANEB) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Anebulo Pharmaceuticals (ANEB) has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anebulo Pharmaceuticals (ANEB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.